BACKGROUND: We aim to directly compare changes in lymphocyte subpopulations between chimeric (rituximab) and humanised (ocrelizumab) anti-CD20 antibodies in multiple sclerosis (MS). METHODS: In this retrospective analysis of prospectively collected data, we included 88 patients with MS, treated with rituximab (n=50) or ocrelizumab (n=38). We used flow cytometry in the peripheral blood to count total lymphocytes and lymphocytes expressing different phenotypic markers (CD4, CD8, CD19, CD20, CD4/CD8 ratio), before treatment and after 1, 3 and 6 months. RESULTS: On linear mixed effect regression models, after 1, 3 and 6 months, patients treated with rituximab and with ocrelizumab were similar in total lymphocyte count, CD19 lymphocytes, CD20 lymphocytes and CD4/CD8 ratio. However, patients treated with ocrelizumab presented with lower CD4 T lymphocytes and CD8 T lymphocytes after 1, 3 and 6 months (all p<0.05). No between-treatment difference in EDSS progression was found. DISCUSSION: B-cell levels in the peripheral blood were equally decreased by rituximab and ocrelizumab. On the contrary, CD4 and CD8 T lymphocyte reduction was more pronounced in ocrelizumab, when compared with rituximab, suggesting a broader immunomodulatory effect for the humanised antibody to be confirmed and correlated with clinical efficacy in the long term.
BACKGROUND: We aim to directly compare changes in lymphocyte subpopulations between chimeric (rituximab) and humanised (ocrelizumab) anti-CD20 antibodies in multiple sclerosis (MS). METHODS: In this retrospective analysis of prospectively collected data, we included 88 patients with MS, treated with rituximab (n=50) or ocrelizumab (n=38). We used flow cytometry in the peripheral blood to count total lymphocytes and lymphocytes expressing different phenotypic markers (CD4, CD8, CD19, CD20, CD4/CD8 ratio), before treatment and after 1, 3 and 6 months. RESULTS: On linear mixed effect regression models, after 1, 3 and 6 months, patients treated with rituximab and with ocrelizumab were similar in total lymphocyte count, CD19 lymphocytes, CD20 lymphocytes and CD4/CD8 ratio. However, patients treated with ocrelizumab presented with lower CD4 T lymphocytes and CD8 T lymphocytes after 1, 3 and 6 months (all p<0.05). No between-treatment difference in EDSS progression was found. DISCUSSION: B-cell levels in the peripheral blood were equally decreased by rituximab and ocrelizumab. On the contrary, CD4 and CD8 T lymphocyte reduction was more pronounced in ocrelizumab, when compared with rituximab, suggesting a broader immunomodulatory effect for the humanised antibody to be confirmed and correlated with clinical efficacy in the long term.
Authors: Yassir M Almatrafi; Mohammed A Babakkor; Muhammed Irfan; Ebaa T Samkari; Waleed M Alzahrani; Doaa K Mohorjy; Sarmad Zahoor; Muhammad T Farooq; Hafiz M Sajid Jehangir Journal: Neurosciences (Riyadh) Date: 2022-04 Impact factor: 0.735
Authors: Roberta Lanzillo; Antonio Carotenuto; Elisabetta Signoriello; Rosa Iodice; Giuseppina Miele; Alvino Bisecco; Giorgia Teresa Maniscalco; Leonardo Sinisi; Felice Romano; Maria Di Gregorio; Luigi Lavorgna; Francesca Trojsi; Marcello Moccia; Mario Fratta; Nicola Capasso; Raffaele Dubbioso; Maria Petracca; Antonio Luca Spiezia; Antonio Gallo; Martina Petruzzo; Marcello De Angelis; Simona Bonavita; Giacomo Lus; Gioacchino Tedeschi; Vincenzo Brescia Morra Journal: J Clin Med Date: 2022-04-07 Impact factor: 4.964
Authors: Rodolfo A Kölliker Frers; Matilde Otero-Losada; Tamara Kobiec; Lucas D Udovin; María Laura Aon Bertolino; María I Herrera; Francisco Capani Journal: Front Immunol Date: 2022-07-28 Impact factor: 8.786
Authors: Valeria Koska; Moritz Förster; Katja Brouzou; Maryam Hatami; Ercan Arat; Ahmet Aytulun; Philipp Albrecht; Orhan Aktas; Patrick Küry; Sven G Meuth; David Kremer Journal: Front Neurol Date: 2021-06-23 Impact factor: 4.003